ApoB and Lp(a): the two cardiovascular numbers your standard German check-up does not measure

ApoB beats LDL-C because it counts the artery-clogging particles themselves, while LDL-C only weighs the cholesterol inside them. Every atherogenic (plaque-forming) lipoprotein carries exactly one ApoB molecule. So ApoB tells you more faithfully how many particles can lodge in your artery wall. The 2019 ESC/EAS guidelines prefer it in key risk settings ^[1].

Your standard cholesterol panel reports LDL-C: the weight of the cholesterol packed inside LDL particles. ApoB sits on all the bad-actor fat carriers: LDL, VLDL, IDL, Lp(a) and chylomicron remnants. Any of them can slip into your artery wall and start a plaque.

For most people, LDL-C and ApoB tell the same story. The trouble starts in the people who matter most for prevention: those with type 2 diabetes, metabolic syndrome, belly fat (central adiposity), or high triglycerides. Their LDL particles tend to be small and cholesterol-poor. So they carry a lot of particles for a given LDL-C mass. Researchers call this mismatch "discordance". Allan Sniderman has spent two decades documenting it ^[3]. For these people, LDL-C quietly underestimates the risk. ApoB tracks it.

That is why the 2019 ESC/EAS dyslipidaemia guidelines gave ApoB a Class I recommendation (their strongest grade) for risk assessment ^[1]. It applies when triglycerides are high, or in diabetes, obesity, metabolic syndrome or very low LDL-C. The 2025 ESC/EAS focused update reaffirmed the LDL-C-based framework but did not revise the ApoB recommendation ^[2]. The US ACC/AHA 2018 cholesterol guideline is more conservative. It counts an ApoB of 130 mg/dL or more as a risk-enhancing factor and suggests measuring it mainly when triglycerides are 200 mg/dL or higher ^[8].

A caveat on how strong the evidence is. The case for ApoB beating LDL-C rests on big observational studies (UK Biobank ^[4], Copenhagen General Population Study) and Mendelian randomization analyses (a genetics method that mimics a trial). We do not yet have a randomized trial that pits "treat to ApoB" against "treat to LDL-C" for hard cardiovascular endpoints. The mechanistic and epidemiological case is strong. It is just not RCT-grade. So read those "ApoB superiority" headlines with that footnote in mind.

Lipoprotein(a) is an LDL-like particle with one extra protein, apolipoprotein(a), bolted on. Your blood level is set more than 90% by your LPA gene ^[5]. Adult levels are usually reached by about age 5, and may creep up a little until adulthood ^[5]. Diet, exercise, statins, and almost every lifestyle lever barely move it. Roughly one in five people of European ancestry carries levels linked to higher atherosclerotic and aortic-valve risk. The prevalence is even higher in people of African ancestry.

The science here is solid. A 2009 JAMA meta-analysis from the Emerging Risk Factors Collaboration pooled 36 prospective studies. It nailed down the independent, continuous link between Lp(a) and coronary heart disease ^[7]. A 2017 "Test in Context" review in JACC then cemented Lp(a) as a causal, independent risk factor ^[6]. The EAS 2022 consensus statement set the modern view ^[5]: every adult should have Lp(a) measured at least once in their lifetime, as part of a full cardiovascular risk assessment.

Now the expectation-management part. As of September 2026, no drug is approved specifically to lower Lp(a). The first big outcome trial has reported, and the result was disappointing. Lp(a)HORIZON tested pelacarsen, an antisense oligonucleotide (a gene-silencing drug) from Ionis/Novartis, in 8,323 people who already had cardiovascular disease and high Lp(a). On 4 September 2026 Novartis announced that the drug lowered Lp(a) but missed its primary endpoint: it did not significantly lower the combined rate of cardiovascular death, heart attack, stroke and urgent coronary revascularization (an emergency procedure to reopen a heart artery) compared with placebo ^[10]. The full data will be presented at a medical congress. Two more outcome trials are still running, and neither has reported:

• OCEAN(a)-Outcomes tests olpasiran, an siRNA (also a gene-silencing drug), from Amgen.
• ACCLAIM-Lp(a) tests lepodisiran, an siRNA, from Eli Lilly.

None of these drugs is approved by the EMA or the FDA. PCSK9 inhibitors (injectable LDL-lowering drugs) do nudge Lp(a) down as a side effect of lowering LDL-C. FOURIER and ODYSSEY OUTCOMES saw roughly 25 to 30%. A pooled 2025 meta-analysis put it at -27% (95% CI -29.8% to -24.1%) ^[9]. They are not licensed for Lp(a) itself.

So what actually changes when you find out your Lp(a) is high? The rest of your risk picture. Guidelines and clinical practice agree on this: hit every modifiable risk factor harder (blood pressure, ApoB-containing lipoproteins, smoking, blood glucose) to offset the Lp(a) burden you cannot change. That recalibration is the real, practical value of the test.

Read your results without panic by treating them as one input, not a verdict. ApoB has no single threshold: your target depends on your overall risk category. Lp(a) risk is continuous, with labs flagging roughly above 50 mg/dL or 105 nmol/L. Always check the units and read both numbers alongside your full risk picture, never a number you found online.

Lab reports use different units and reference ranges. That alone causes half the confusion. ApoB shows up in g/L or mg/dL. Lp(a) shows up either in mass units (mg/dL) or, the ESC/EAS preference, in molar units (nmol/L). The two are not interchangeable, because Lp(a) isoforms vary in size. Always check which unit your report uses before you compare yourself to a number you read online.

For ApoB, the 2019 ESC/EAS guideline sets goals by your overall cardiovascular risk category, not by one single threshold ^[1]. People at very high risk are expected to reach a much lower ApoB than people at low risk. Same logic as LDL-C. This risk-stratified approach remains the standard. A single number on a screen, cut off from your age, blood pressure, smoking status, family history, and other risk factors, cannot tell you what your target should be. That is a conversation for your Kardiologin or Hausärztin.

For orientation, here are the reference values from the guidelines:

Marker	Value	What it means
ApoB	under 65 mg/dL (0.65 g/L)	ESC/EAS goal at very high risk [1]
ApoB	under 80 mg/dL (0.80 g/L)	goal at high risk [1]
ApoB	under 100 mg/dL (1.0 g/L)	goal at moderate risk [1]
Lp(a)	under 30 mg/dL (about 75 nmol/L)	risk from Lp(a) unlikely [5]
Lp(a)	30 to 50 mg/dL	grey zone [5]
Lp(a)	above 50 mg/dL (105 to 125 nmol/L)	elevated, adds to your overall risk [2, 5]
Lp(a)	above 180 mg/dL (430 nmol/L)	lifetime risk like familial hypercholesterolaemia [5]

For Lp(a), the EAS 2022 consensus calls the risk continuous and graded ^[5]. There is no clean cut-off where danger suddenly starts. Many labs flag values above roughly 50 mg/dL or 105 to 125 nmol/L as elevated. Those flags are conventions, not biology. Isoform-correction varies between methods, and the 2025 ESC/EAS Focused Update on dyslipidaemia uses 105 nmol/L specifically ^[2]. Very high values (say, above 180 mg/dL or 430 nmol/L) carry a lifetime cardiovascular risk equivalent to untreated heterozygous familial hypercholesterolaemia, an inherited high-cholesterol condition ^[5]. That is well above a simple doubling of the general-population baseline. Your number is one input among many.

Two practical things to keep in mind. First, read both markers alongside a full lipid panel, hs-CRP (an inflammation marker), blood pressure, glucose or HbA1c (your average blood sugar over about three months), and a well-documented family history. Second, primary prevention (you have never had an event) and secondary prevention (you have) follow different treatment logics. The same Lp(a) value means different things in those two contexts.

Your Hausärztin skips ApoB and Lp(a) because the statutory Check-up 35 does not include them. That check-up (Gesundheitsuntersuchung) covers a basic lipid panel: total cholesterol, HDL-C, LDL-C, triglycerides. Kassenpatienten (people with statutory insurance) can claim it every three years from age 35. hs-CRP, fasting insulin and HbA1c are not on it either, outside specific clinical reasons. Your Hausärztin is doing exactly what the GKV check-up specifies. She just is not doing what a longevity-curious patient might want her to add on.

This is not a German quirk born of neglect. Most national primary-care systems anchor on LDL-C, because LDL-C is what most of the trial evidence and risk scores were built on. ApoB and Lp(a) only entered the guidelines as risk-refiners more recently. And primary-care reimbursement schedules trail the guidelines by years. The DGFF (Deutsche Gesellschaft zur Bekämpfung von Fettstoffwechselstörungen, also known as Lipid-Liga) pushes hard for broader Lp(a) testing, but coverage decisions sit with the G-BA (the Federal Joint Committee that decides what statutory insurance pays), not the medical societies.

So for most patients the practical answer is simple. ApoB and Lp(a) are usually IGeL (Individuelle Gesundheitsleistung), meaning self-pay add-ons, unless you have a clear clinical indication. Both do have their own codes in the statutory fee catalogue (EBM 32452 for ApoB, EBM 32456 for Lp(a)), so your doctor can bill the Kasse when there is a medical reason ^[11]. Indications that might shift them into Kassen-paid territory:

• known coronary artery disease
• premature familial cardiovascular disease
• statin intolerance
• very high LDL-C that raises suspicion of familial hypercholesterolaemia
• recurrent events despite well-controlled LDL-C

Bring a documented family history. It is the single most useful thing you can hand a GP making this call.

If your Hausärztin declines to order them, that is normal. It is not an insult to her judgement. Your realistic options: ask her to add them as an IGeL/Selbstzahler line on your next lab draw, or use a Selbstzahler service that orders from a major lab like Synlab, Limbach, or Sonic on your behalf. Both routes use the same labs.

As a Selbstzahler in Germany, Lp(a) tends to run about 20 to 40 EUR and ApoB about 10 to 25 EUR per marker. Add venepuncture (the blood draw) and a service fee on top. All three big laboratory networks run both tests: Synlab, Limbach and Sonic Healthcare (with Bioscientia, Labor Schottdorf in Augsburg and others). Either your Hausärztin orders them and bills you privately under GOÄ (Gebührenordnung für Ärzte, the private fee schedule), or you use a Selbstzahler service that ships your blood to one of those same labs. The exact number depends on the lab, the region and whether the markers are part of a wider panel. Verify before you order. Online prices drift, and some are promotional.

Marker	GOÄ code	GOÄ fee (1.15x)	Self-pay, roughly	Statutory insurance
ApoB	3725	13.41 EUR	10 to 25 EUR	only with an indication
Lp(a)	3730	20.11 EUR	20 to 40 EUR	only with an indication

The blood draw and any service fee come on top ^[12].

In Austria, the Wahlarzt model is the usual route. A Wahlarzt or Wahlarzt-Labor draws your blood, bills you privately, and you submit the invoice to your Krankenkasse for partial reimbursement under standard rules. You typically get back around 80% of the equivalent Kassen tariff. For niche markers like Lp(a), that can be a lot less than you actually paid. ÖGK (Österreichische Gesundheitskasse, the main statutory insurer) does not generally reimburse Lp(a) testing outside specific clinical indications.

In Switzerland both tests are on the federal Analysenliste, the list of lab tests basic insurance (OKP) pays for, with no special limits. The tariff is 17.9 tax points each, at 1 CHF per point, so roughly 36 CHF for both before order fees, the blood draw and the consultation ^[13]. If your Hausarzt or Kardiologe orders them for a medical reason, OKP pays and the bill counts toward your Franchise (annual deductible) and Selbstbehalt (your share above it). Pure lifestyle screening without an indication you usually pay yourself, and self-pay online services often charge well above the tariff.

A few practical tips travel across all three countries. Fast for 10 to 12 hours if your panel includes triglycerides and your doctor agrees. ApoB and Lp(a) themselves are not strongly fasting-dependent, but the rest of the panel may be. Sit calmly for ten minutes before the draw. Avoid drawing during an acute illness, which can shift lipids. Lp(a) can also run higher in some inflammatory conditions, though the effect is usually small ^[5]. Ask the lab in advance which Lp(a) unit it reports (mg/dL or nmol/L) and which assay it uses. Prefer an isoform-insensitive assay, one that reads correctly whatever the size of your Lp(a) particles ^[5].

First, and most important: this guide does not prescribe a protocol. If your ApoB or Lp(a) comes back elevated, your next step is a conversation. With your Hausärztin, or better, a Kardiologin or a lipidology-trained Wahlärztin/Wahlarzt. The decision tree branches heavily on your age, your other risk factors, your family history, and whether you are in primary or secondary prevention. There is no single right answer.

So what makes that conversation productive? Bring your full lipid panel, a documented family history of cardiovascular events (with ages), your blood pressure trend, glucose or HbA1c if you have it, your smoking status, and a list of medications. Ask explicit questions. Do not expect your doctor to volunteer them. Useful ones:

• "Where does my overall ESC SCORE2 risk land?" (SCORE2 is the ESC's 10-year cardiovascular risk calculator.)
• "Does my Lp(a) push me into a higher-risk band that changes how aggressively we treat my LDL-C and blood pressure?"
• "Is a coronary calcium score (CAC) reasonable for me as a tiebreaker?"
• "Are there indications for lipid-lowering therapy that I meet, given my full picture?"

On lifestyle, read this part carefully. The Mediterranean dietary pattern, regular aerobic and resistance exercise, not smoking, sleeping enough, and keeping belly fat (central adiposity) in check all improve cardiovascular outcomes and modestly improve ApoB-containing lipoproteins. They will not normalize a genetically high Lp(a). Treating lifestyle as "the Lp(a) protocol" is exactly the magical thinking this guide is trying to avoid. Lifestyle is worth doing on its own merits, whatever your Lp(a) is. Frame it that way.

One last word on the longevity-medicine framing that floats around social media. It is useful for some people to know their ApoB and Lp(a) earlier rather than later, especially those with a strong family history of premature cardiovascular events. It is not useful for an asymptomatic healthy person with no family history to spiral into anxiety over a single elevated number. Test if you can act on the result with a clinician you trust. Otherwise, the test is just information you cannot use.